Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G7KJ
|
||||
| Former ID |
DAP001184
|
||||
| Drug Name |
Diflorasone
|
||||
| Synonyms |
Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses [ICD10:L20-L30] | Approved | [1] | ||
| Therapeutic Class |
Antiinflammatory Agents
|
||||
| Company |
Pharmacia And Upjohn Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H32F2O7
|
||||
| InChI |
InChI=1S/C26H32F2O7/c1-13-8-17-18-10-20(27)19-9-16(31)6-7-23(19,4)25(18,28)21(32)11-24(17,5)26(13,35-15(3)30)22(33)12-34-14(2)29/h6-7,9,13,17-18,20-21,32H,8,10-12H2,1-5H3/t13-,17-,18-,20-,21-,23-,24-,25-,26-/m0/s1
|
||||
| InChIKey |
BOBLHFUVNSFZPJ-JOYXJVLSSA-N
|
||||
| CAS Number |
CAS 2557-49-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
855657, 7848390, 8194611, 11466647, 11467767, 11486513, 14761903, 24894203, 29215002, 43127743, 47365371, 47589149, 47736650, 48035306, 49699029, 50019411, 50103984, 56422226, 57318190, 57654135, 71840216, 76963292, 85787968, 92125524, 92720069, 99319112, 103770528, 103914477, 104350411, 117575834, 121363195, 124799710, 126620401, 131310944, 134338429, 135030323, 136135911, 137005254, 139836966, 144115906, 144204426, 160963571, 163134097, 163835798, 164822906, 170465294, 175268136, 175611936, 178103647, 179116650
|
||||
| SuperDrug ATC ID |
D07AC10
|
||||
| SuperDrug CAS ID |
cas=002557495
|
||||
| Target and Pathway | |||||
| Target(s) | Phospholipase A2 | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Phospholipases | ||||
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Ether lipid metabolism | |||||
| Arachidonic acid metabolism | |||||
| Linoleic acid metabolism | |||||
| alpha-Linolenic acid metabolism | |||||
| Metabolic pathways | |||||
| Ras signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Pancreatic secretion | |||||
| Fat digestion and absorption | |||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
| Reactome | Acyl chain remodelling of PC | ||||
| Acyl chain remodelling of PE | |||||
| Acyl chain remodelling of PI | |||||
| WikiPathways | Glycerophospholipid biosynthesis | ||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. Epub 2008 Oct 18. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.